ReviewNPJ vaccines2023
Healthy ageing: Herpes zoster infection and the role of zoster vaccination.
Review in NPJ vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 3 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Current advances in the epidemiology, risk factors, prevention, management, and long-term outcomes of herpes zoster and post-herpetic neuralgia.Frontiers in microbiology · 2026Pooled it
- Global herpes zoster burden in adults with COPD: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- Advancements in Herpes Zoster Diagnosis, Treatment, and Management: Systematic Review of Artificial Intelligence Applications.Journal of medical Internet research · 2025Pooled it
- Immunogenicity and Safety of the Adjuvanted Respiratory Syncytial Virus Prefusion F Protein-Based Vaccine When Co-administered With the Adjuvanted Recombinant Herpes Zoster Subunit Vaccine in Adults ≥ 50 Years of Age.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Trial
- Herpes zoster knowledge, attitudes, and herpes zoster vaccine acceptability among patients in a tertiary hospital and dermatologists in the Philippines: A cross-sectional study.Human vaccines & immunotherapeutics · 2026Article
- Review
- Efficacy of Ultrasound-Guided Intercostal Nerve Block With Liposomal Bupivacaine for Treating Postherpetic Neuralgia in Adult Patients.The Kaohsiung journal of medical sciences · 2026Article
- Unlocking herpes zoster vaccination value in Finland: return on investment and actuarial model.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- A case report of shingles and subsequent cardiac ischaemia in a young male.European heart journal. Case reports · 2026Article
- Mitigating Vaccine Disparities Through Faith-Based Intervention: A Pre-Post Analysis of Recombinant Zoster Vaccine Knowledge and Acceptance in Socially Vulnerable Racial and Ethnic Minoritized Communities.Infectious diseases and therapy · 2026Article
- Metformin attenuates HSV-1-induced neuropathic pain by restoring Sirt3-mediated mitophagy.Cell communication and signaling : CCS · 2026Article
- Design and mechanistic insights into ZMF59/CpG: a complementary adjuvant system boosting immunity and safety in herpes zoster vaccines.Journal of nanobiotechnology · 2026Article
- Post-COVID varicella-zoster virus reactivation: lowering the immunological threshold for latency breakdown.Frontiers in cellular and infection microbiology · 2026Review
- Causal Brain Network Alterations Across Disease Stages in Herpes Zoster and Postherpetic Neuralgia.Journal of pain research · 2026Article
- Clinical epidemiology of herpes zoster and postherpetic neuralgia in Barcelona (Spain). A single-center study.Frontiers in public health · 2026Article
- Attitudes toward and regional utilization of age-specific vaccinations from the age of 60 in Saxony-Anhalt.Research in health services & regions · 2025Article
- Clinical and economic burden of herpes zoster in Mexico: A retrospective medical chart analysis in a private healthcare setting.Human vaccines & immunotherapeutics · 2025Article
- Herpes zoster vaccination and vaccine preferences among persons aged 50-64 years in Australia: Findings from a discrete choice experiment.Human vaccines & immunotherapeutics · 2025Article
- Patient preferences toward herpes zoster vaccination among individuals aged 50 years or older in South Korea: Findings from a discrete choice experiment.Human vaccines & immunotherapeutics · 2025Article
- Vaccination Against Herpes Zoster in Adults: Current Strategies in European Union Countries.Vaccines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Populations are ageing worldwide, with considerable time lived in ill-health, putting upwards pressure on healthcare budgets. Healthy ageing is defined as maintaining functional ability, including the ability to: meet basic needs; learn, grow and make decisions; be mobile; build and maintain relationships; and contribute to society. The risk and impact of infectious diseases increase with age due to immunosenescence. Vaccination can help to prevent disease in older adults, promoting healthy ageing and active lives. Herpes zoster (HZ) occurs when the varicella zoster virus is reactivated due to declining immunity. HZ is common, with a lifetime risk of one-third, and increases in incidence with age. HZ is associated with severe and intense pain, substantially affecting the functional status of patients as well as their overall health-related quality of life. HZ and its complications may result in prolonged morbidity, including persistent pain (post-herpetic neuralgia, PHN), hearing impairment, vision loss and increased risk of stroke and myocardial infarction. HZ and PHN are difficult to treat, substantiating the benefits of prevention. Vaccines to prevent HZ include a recombinant zoster vaccine (RZV). RZV has shown efficacy against the HZ burden of disease and HZ burden of interference on activities of daily living of over 90% in immunocompetent adults aged ≥50 years. Vaccine efficacy against HZ was maintained at over 70% at 10 years post-vaccination. Adult vaccination, including against HZ, has the potential to reduce burden of disease, thus helping to maintain functioning and quality of life to support healthy ageing in older adults.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.